• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Erivedge (vismodegib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Erivedge (vismodegib)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Erivedge (vismodegib) is an inhibitor of the hedgehog (Hh) signaling pathway. The pathway promotes cellular development and division in several cell types, both through direct cellular activation and through secondary activation of multiple pathways of tissue generation, including angiogenesis and tissue growth. The pathway is typically over-activated in basal cell carcinoma.

    Erivedge is specifically approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

    Erivedge is supplied as a tablet for oral administration. The recommended initial dose of Erivedge is 150 mg taken orally once daily until disease progression or until unacceptable toxicity. If a dose of Erivedge is missed, do not make up that dose; resume dosing with the next scheduled dose.

    Clinical Results

    FDA Approval
    The FDA approval of Erivedge was based on an international, single-arm, multi-center, open-label, two-cohort trial. The trial enrolled 104 subjects with either metastatic basal cell carcinoma (mBCC) or locally advanced BCC (laBCC). The subjects received 150 mg vismodegib per day orally until disease progression or unacceptable toxicity. The median duration of treatment was 10.2 months. The major efficacy outcome measure of the trial was objective response rate (ORR). In the mBCC cohort, tumor response was assessed according to RECIST criteria. In the laBCC cohort, tumor response evaluation included measurement of externally assessable tumor (including scar) and assessment for ulceration in photographs, radiographic assessment of target lesions (if appropriate), and tumor biopsy. Of the 104 subjects enrolled, 96 were evaluable for ORR. In the mBCC cohort, 30.3% reported an ORR and in the laBCC cohort 42.9% reported an ORR. The median response duration in both arms was 7.6 months.

    Side Effects

    Adverse events associated with the use of Erivedge may include, but are not limited to, the following:

    • muscle spasms
    • alopecia
    • dysgeusia
    • weight loss
    • fatigue
    • nausea
    • diarrhea
    • decreased appetite
    • constipation
    • arthralgias
    • vomiting
    • ageusia

    Mechanism of Action

    Erivedge (vismodegib) is an inhibitor of the hedgehog (Hh) signaling pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction. The Hh pathway promotes cellular development and division in several cell types, both through direct cellular activation and through secondary acivation of multiple pathways of tissue generation, including angiogenesis and tissue growth. The pathway is typically over-activated in basal cell carcinoma through downregulation of Hedgehog inhibition.

    Literature References

    Amin SH, Tibes R, Kim JE, Hybarger CP Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. The Laryngoscope 2010 Dec;120(12):2456-9. doi: 10.1002/lary.21145

    Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. The New England Journal of Medicine 2009 Sep 17;361(12):1164-72

    Additional Information

    For additional information regarding Erivedge or basal cell carcinoma, please visit the Genentech products web page.

    Approval Date: 2012-01-01
    Company Name: Genentech
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing